BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Lymphoma (DLBCL, follicular, Hodgkin, MCL) clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for lymphoma: 663 (315 sponsors; 63 newly posted in the last 180 days, 28 stopped in the last 180 days; 24 new-entrant sponsors). Momentum score 11.2, rank 61 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 11, Phase 1 189, Phase 2 258, Phase 3 115, Phase 4 8, N/A 82.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Merck Sharp & Dohme LLC MRK20P2 11, P3 932
BeOne Medicines ONC16P3 7, P1 2, P2 731
Hoffmann-La Roche18P3 6, P1 3, P2 7, NA 202
Genmab GMAB14P3 6, P2 7, P1 101
AstraZeneca AZN22P3 5, P1 2, P2 13, NA 223
Beijing InnoCare Pharma Tech Co., Ltd.9P2 4, P3 521
Regeneron Pharmaceuticals REGN9P2 2, P3 5, P1 1, NA 111
Loxo Oncology, Inc.6P3 5, P2 100
Novartis Pharmaceuticals NVS12P2 4, NA 2, P1 3, P3 303
Ascentage Pharma Group Inc. AAPG10P2 3, P3 3, P1 402
Incyte Corporation INCY8P1 3, P2 2, P3 312
Dizal Pharmaceuticals7P3 3, P2 410
Kite, A Gilead Company7P1 2, P3 3, P2 200
Janssen Research & Development, LLC11P1 7, P2 2, P3 202
Acerta Pharma BV6P2 3, P3 2, P1 102
Celgene6P1 1, P2 3, P3 201
Sinocelltech Ltd.4P2 1, P3 2, P1 110
AbbVie ABBV11P1 5, NA 2, P3 1, P2 312
Guangzhou Lupeng Pharmaceutical Company LTD.8P2 4, P1 3, P3 121
Nurix Therapeutics, Inc. NRIX6P1 3, P2 2, P3 101
Pfizer PFE6P1 1, P4 2, NA 1, P3 1, P2 100
Ono Pharmaceutical Co., Ltd.5P3 1, P1 3, P2 100
Evopoint Biosciences Inc.4P2 3, P3 111
Amgen AMGN3P2 2, P3 100
Chengdu Zenitar Biomedical Technology Co., Ltd3P2 2, P3 101

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Karyopharm Therapeutics Inc KPTIQNCT02227251 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse Large B-cell Lymphomaactive not recruiting244
2026-12 est.P2/P3Karyopharm Therapeutics Inc KPTIQNCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruiting501
2026-12 est.P2Ascentage Pharma Group Inc. AAPGNCT05147467 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLChronic Lymphocytic Leukemia; Small Lymphocytic Lymphomarecruiting75
2026-12 est.P1/P2Step Pharma, SASNCT05463263 A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell LymphomasLymphoma, B-Cell; Lymphoma, T-Cellrecruiting180
2026-12 est.P1/P2Dren BioNCT05475925 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasLGLL - Large Granular Lymphocytic Leukemia; Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Primary Crecruiting200
2026-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05623982 A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNon-hodgkin's Lymphomarecruiting40
2026-12 est.P1/P2Beam Therapeutics Inc. BEAMNCT05885464 A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LLLymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemiaactive not recruiting5
2026-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06066203 A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological MalignanciesNon-hodgkin's Lymphomarecruiting40
2026-12 est.P2Ryvu Therapeutics SANCT06534437 MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)Non-Hodgkin Lymphoma, B-cellrecruiting178
2026-12-23 est.P1/P2Cho Pharma Inc.NCT05950165 A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaNon-Hodgkin Lymphomaactive not recruiting37
2026-12-28 est.P1/P2Hoffmann-La RocheNCT04077723 A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination WitLymphoma, Non-Hodgkinactive not recruiting498
2026-12-30 est.P2Chengdu Zenitar Biomedical Technology Co., LtdNCT05563844 Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)Diffuse Large B Cell Lymphoma,DLBCLactive not recruiting74
2026-12-30 est.P2Allotera TherapeuticsNCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphomarecruiting125
2026-12-31 est.P3Janssen Research & Development, LLCNCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib)Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma;active not recruiting539
2026-12-31 est.P2Miltenyi Biomedicine GmbHNCT04792489 DALY II USA/ MB-CART2019.1 for DLBCLRefractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Graderecruiting315
2026-12-31 est.P2GeoVax, Inc. GOVXNCT04977024 SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerCOVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myelactive not recruiting63
2026-12-31 est.P1/P2Pell Bio-Med Technology Co., Ltd.NCT05326243 Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell LymphomaDiffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Large B-cell Lymphoma; Folactive not recruiting49
2026-12-31 est.P1/P2Genfleet Therapeutics (Shanghai) Inc.NCT06375733 A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLLarge B-cell Lymphomarecruiting51
2026-12-31 est.P1/P2Xenothera SASNCT06495723 Polyspecific Antibodies in Lymphoproliferative T-cell DisordersPeripheral T Cells Lymphoma (PTCL)recruiting54
2027-01 est.P2Evopoint Biosciences Inc.NCT06702605 To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaRelapsed/Refractory Peripheral T Cell Lymphomanot yet recruiting50
2027-01 est.P2Zhejiang Teruisi Pharmaceutical Inc.NCT06886139 A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.CD20-positive Diffuse Large B-Cell Lymphomanot yet recruiting139
2027-01-31 est.P2Miltenyi Biomedicine GmbHNCT07288879 DALY II Japan/MB-CART2019.1 for DLBCLDLBCL - Diffuse Large B Cell Lymphoma; CAR T Cell Therapyrecruiting31
2027-02-12 est.P2Merck Sharp & Dohme LLC MRKNCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Hodgkin Lymphomaactive not recruiting340
2027-02-13 est.P3Epizyme, Inc.NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo inRelapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphomaactive not recruiting599
2027-02-15 est.P3Acerta Pharma BVNCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLLymphoma, Mantle Cellactive not recruiting635

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Oncternal Therapeutics, IncNCT05431179 A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaLymphoma, Mantle-Cell; Lymphoma; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferatwithdrawn
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-22P1/P2Hoffmann-La RocheNCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaNon-Hodgkins Lymphomacompleted211
2026-10-13 est.P1/P2GlaxoSmithKlineNCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerMelanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinactive not recruiting83
2026-10-01 est.P2PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07188610 PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaCD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphomarecruiting100
2026-10 est.P3Loxo Oncology, Inc.NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphomaactive not recruiting600
2026-09-30 est.P2Hebei Senlang Biotechnology Inc., Ltd.NCT07244380 Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.T Lymphoblastic Leukemia/Lymphomanot yet recruiting38
2026-09-30 est.P1/P2Turning Point Therapeutics, Inc. TPBNCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsLocally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma; Primary CNS Tumorsrecruiting75
2026-09-01 est.P1/P2Zhejiang Teruisi Pharmaceutical Inc.NCT07035379 A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCLDiffuse Large B-Cell Lymphoma (DLBCL)not yet recruiting66
2026-09-01 est.P3Incyte Corporation INCYNCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsDiffuse Large B-cell Lymphomaactive not recruiting899
2026-08-11P1/P2Bristol-Myers Squibb BMYNCT06035497 A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas iRelapsed or Refractory T-cell Lymphomasactive not recruiting83
2026-07-31 est.P2Xynomic Pharmaceuticals, Inc.NCT03936153 Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell Lymphoma (DLBCL)recruiting170
2026-07-14P1/P2Ossium Health, Inc.NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignAcute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; Aactive not recruiting12
2026-06-30 est.P2NOBO MedicineNCT06737250 NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSLPrimary CNS Lymphoma (PCNSL)recruiting33
2026-06-30 est.P2Chengdu Zenitar Biomedical Technology Co., LtdNCT06485219 A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaRelapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL)active not recruiting50
2026-06-22 est.P2Cellectar Biosciences, Inc. CLRBNCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromWaldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymactive not recruiting120
2026-06-20 est.P1/P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05055791 A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic MalignanciesAcute Myeloid Leukemia; Lymphoma; Multiple Myelomaunknown312
2026-06-19P2CelgeneNCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaLymphoma, Follicularactive not recruiting95
2026-06-17P2Regeneron Pharmaceuticals REGNNCT03888105 A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With OtB-cell Non-Hodgkin Lymphoma (B-NHL)active not recruiting515
2026-06-10P2Dizal PharmaceuticalsNCT06539195 DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)Diffuse Large B Cell Lymphomacompleted59
2026-06-10P2Genmab GMABNCT05660967 Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphomaterminated111
2026-06-03P3Hoffmann-La RocheNCT04712097 A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Relapsed or Refractory Follicular Lymphomaactive not recruiting478
2026-06 est.P1/P2Juventas Cell Therapy Ltd.NCT06005649 Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaNon-hodgkin Lymphomawithdrawn
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350
2026-05-31 est.P2Ascentage Pharma Group Inc. AAPGNCT04496349 A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLT-Prolymphocytic Leukemia; Non-Hodgkins Lymphomarecruiting78
2026-05-27P1/P2Lakefront Biotherapeutics NV LKFTNCT06561425 A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma; Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cellterminated130
2026-05-23P2Hutchmed HCMNCT06601504 Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRelapsed/Refractory Diffuse Large B-Cell Lymphomacompleted61

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "lymphoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.